RNA rewriting, recoding, and rewiring in human disease

Trends in Molecular Medicine

Volumn 21, Issue 9, 2015, Pages 549-559

  Zipeto, Maria Anna ^a,b   Jiang, Qingfei ^a,b   Melese, Etienne ^c   Jamieson, Catriona H M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ADAR; Degenerative disease; Human disease; RNA editing

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE ACTING ON RNA; ADENOSINE DEAMINASE ACTING ON RNA 1; APOLIPOPROTEIN E; CALCIUM; HYDROLASE; INOSINE; MICRORNA; RNA; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ALU SEQUENCE; BINDING SITE; CANCER RESEARCH; CELL MIGRATION; CELL PROLIFERATION; DEAMINATION; DEGENERATIVE DISEASE; EXCITOTOXICITY; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; MOTONEURON; NEOPLASM; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PATHOGENESIS; PROTEIN PROCESSING; REVIEW; RNA EDITING; RNA INTERFERENCE; TRANSCRIPTOMICS; TRYPANOSOMA; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM;

ADENOSINE DEAMINASE; ANIMALS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; RNA; RNA EDITING;

EID: 84940592839     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.07.001     Document Type: Review

References (105)

1. Benne R., et al. Major transcript of the frameshifted coxII gene from trypanosome mitochondria contains four nucleotides that are not encoded in the DNA. Cell 1986, 46:819-826.
2. O'Connell M.A., Keller W. Purification and properties of double-stranded RNA-specific adenosine deaminase from calf thymus. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:10596-10600.
3. Kim U., et al. Purification and characterization of double-stranded RNA adenosine deaminase from bovine nuclear extracts. J. Biol. Chem. 1994, 269:13480-13489.
4. Bahn J.H., et al. Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways. Nat. Commun. 2015, 6:6355.
5. Morse D.P., et al. RNA hairpins in noncoding regions of human brain and Caenorhabditis elegans mRNA are edited by adenosine deaminases that act on RNA. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7906-7911.
6. Bass B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 2002, 71:817-846.
7. Bass B.L., et al. A standardized nomenclature for adenosine deaminases that act on RNA. RNA 1997, 3:947-949.
8. George C.X., et al. Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing. J. Biol. Chem. 2005, 280:15020-15028.
9. Patterson J.B., Samuel C.E. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol. Cell. Biol. 1995, 15:5376-5388.
10. Patterson J.B., et al. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 1995, 210:508-511.
11. Wang Y., et al. Genomic organization and chromosomal location of the human dsRNA adenosine deaminase gene: the enzyme for glutamate-activated ion channel RNA editing. J. Mol. Biol. 1995, 254:184-195.
12. Weier H.U., et al. The interferon-inducible, double-stranded RNA-specific adenosine deaminase gene (DSRAD) maps to human chromosome 1q21.1-21.2. Genomics 1995, 30:372-375.
13. Eckmann C.R., et al. The human but not the Xenopus RNA-editing enzyme ADAR1 has an atypical nuclear localization signal and displays the characteristics of a shuttling protein. Mol. Biol. Cell 2001, 12:1911-1924.
14. Fritz J., et al. RNA-regulated interaction of transportin-1 and exportin-5 with the double-stranded RNA-binding domain regulates nucleocytoplasmic shuttling of ADAR1. Mol. Cell. Biol. 2009, 29:1487-1497.
15. Herbert A., et al. A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:8421-8426.
16. Herbert A., Rich A. The role of binding domains for dsRNA and Z-DNA in the in vivo editing of minimal substrates by ADAR1. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:12132-12137.
17. Gerber A., et al. Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. RNA 1997, 3:453-463.
18. Maas S., Gommans W.M. Novel exon of mammalian ADAR2 extends open reading frame. PLoS ONE 2009, 4:e4225.
19. Mittaz L., et al. Cloning of a human RNA editing deaminase (ADARB1) of glutamate receptors that maps to chromosome 21q22.3. Genomics 1997, 41:210-217.
20. Desterro J.M., et al. Dynamic association of RNA-editing enzymes with the nucleolus. J. Cell Sci. 2003, 116:1805-1818.
21. Sansam C.L., et al. Modulation of RNA editing by functional nucleolar sequestration of ADAR2. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:14018-14023.
22. Chen C.X., et al. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 2000, 6:755-767.
23. Cho D.S., et al. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J. Biol. Chem. 2003, 278:17093-17102.
24. Poulsen H., et al. Dimerization of ADAR2 is mediated by the double-stranded RNA binding domain. RNA 2006, 12:1350-1360.
25. Valente L., Nishikura K. RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions. J. Biol. Chem. 2007, 282:16054-16061.
26. Savva Y.A., et al. Auto-regulatory RNA editing fine-tunes mRNA re-coding and complex behaviour in Drosophila. Nat. Commun. 2012, 3:790.
27. Benne R. RNA editing. The long and the short of it. Nature 1996, 380:391-392.
28. Lomeli H., et al. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science 1994, 266:1709-1713.
29. Higuchi M., et al. RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell 1993, 75:1361-1370.
30. Sommer B., et al. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991, 67:11-19.
31. Rueter S.M., et al. Regulation of alternative splicing by RNA editing. Nature 1999, 399:75-80.
32. Bazak L., et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014, 24:365-376.
33. Scadden A.D. The RISC subunit Tudor-SN binds to hyper-edited double-stranded RNA and promotes its cleavage. Nat. Struct. Mol. Biol. 2005, 12:489-496.
34. Daniel C., et al. Alu elements shape the primate transcriptome by cis-regulation of RNA editing. Genome Biol. 2014, 15:R28.
35. Ramaswami G., et al. Accurate identification of human Alu and non-Alu RNA editing sites. Nat. Methods 2012, 9:579-581.
36. Zhang Z., Carmichael G.G. The fate of dsRNA in the nucleus: a p54(nrb)-containing complex mediates the nuclear retention of promiscuously A-to-I edited RNAs. Cell 2001, 106:465-475.
37. Yang W., et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat. Struct. Mol. Biol. 2006, 13:13-21.
38. Lee Y., et al. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002, 21:4663-4670.
39. Kawahara Y., et al. RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. EMBO Rep. 2007, 8:763-769.
40. Luciano D.J., et al. RNA editing of a miRNA precursor. RNA 2004, 10:1174-1177.
41. Heale B.S., et al. Editing independent effects of ADARs on the miRNA/siRNA pathways. EMBO J. 2009, 28:3145-3156.
42. Ota H., et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 2013, 153:575-589.
43. Kume H., et al. A-to-I editing in the miRNA seed region regulates target mRNA selection and silencing efficiency. Nucleic Acids Res. 2014, 42:10050-10060.
44. Vesely C., et al. Adenosine deaminases that act on RNA induce reproducible changes in abundance and sequence of embryonic miRNAs. Genome Res. 2012, 22:1468-1476.
45. Ekdahl Y., et al. A-to-I editing of microRNAs in the mammalian brain increases during development. Genome Res. 2012, 22:1477-1487.
46. Alon S., et al. Systematic identification of edited microRNAs in the human brain. Genome Res. 2012, 22:1533-1540.
47. Borchert G.M., et al. Adenosine deamination in human transcripts generates novel microRNA binding sites. Hum. Mol. Genet. 2009, 18:4801-4807.
48. Shah S.P., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
49. Li M., et al. Widespread RNA and DNA sequence differences in the human transcriptome. Science 2011, 333:53-58.
50. Pickrell J.K., et al. Comment on 'Widespread RNA and DNA sequence differences in the human transcriptome'. Science 2012, 335:1302.
51. Lin W., et al. Comment on 'Widespread RNA and DNA sequence differences in the human transcriptome'. Science 2012, 335:1302.
52. Kleinman C.L., Majewski J. Comment on 'Widespread RNA and DNA sequence differences in the human transcriptome'. Science 2012, 335:1302.
53. Crews L.A., et al. An RNA editing fingerprint of cancer stem cell reprogramming. J. Transl. Med. 2015, 13:52.
54. Hartner J.C., et al. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J. Biol. Chem. 2004, 279:4894-4902.
55. Hartner J.C., et al. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat. Immunol. 2009, 10:109-115.
56. Wang Q., et al. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science 2000, 290:1765-1768.
57. Wang Q., et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J. Biol. Chem. 2004, 279:4952-4961.
58. Qiu W., et al. ADAR1 is essential for intestinal homeostasis and stem cell maintenance. Cell Death Dis. 2013, 4:e599.
59. XuFeng R., et al. ADAR1 is required for hematopoietic progenitor cell survival via RNA editing. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17763-17768.
60. Higuchi M., et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 2000, 406:78-81.
61. Paz N., et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007, 17:1586-1595.
62. Jiang Q., et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:1041-1046.
63. Beghini A., et al. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. Hum. Mol. Genet. 2000, 9:2297-2304.
64. Cenci C., et al. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J. Biol. Chem. 2008, 283:7251-7260.
65. Maas S., et al. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:14687-14692.
66. Choudhury Y., et al. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J. Clin. Invest. 2012, 122:4059-4076.
67. Kawahara Y., et al. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science 2007, 315:1137-1140.
68. Tomaselli S., et al. Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. Genome Biol. 2015, 16:5.
69. Nemlich Y., et al. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J. Clin. Invest. 2013, 123:2703-2718.
70. Shoshan E., et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat. Cell Biol. 2015, 17:311-321.
71. Chen L., et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 2013, 19:209-216.
72. Qin Y.R., et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 2014, 74:840-851.
73. Han S.W., et al. RNA editing in RHOQ promotes invasion potential in colorectal cancer. J. Exp. Med. 2014, 211:613-621.
74. Liu Q., et al. Two novel mutations and evidence for haploinsufficiency of the ADAR gene in dyschromatosis symmetrica hereditaria. Br. J. Dermatol. 2006, 154:636-642.
75. Kono M., et al. Novel ADAR1 mutations including a single amino acid deletion in the deaminase domain underlie dyschromatosis symmetrica hereditaria in Japanese families. Int. J. Dermatol. 2014, 53:e194-e196.
76. Rice G.I., et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat. Genet. 2012, 44:1243-1248.
77. Liu Q., et al. Five novel mutations in the ADAR1 gene associated with dyschromatosis symmetrica hereditaria. BMC Med. Genet. 2014, 15:69.
78. Laxminarayana D., et al. Transcript mutations of the alpha regulatory subunit of protein kinase A and up-regulation of the RNA-editing gene transcript in lupus T lymphocytes. Lancet 2002, 360:842-849.
79. Brusa R., et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 1995, 270:1677-1680.
80. Gaisler-Salomon I., et al. Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease. Neurobiol. Aging 2014, 35:1785-1791.
81. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med. 2007, 11:1227-1238.
82. Akbarian S., et al. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Brain Res. 1995, 699:297-304.
83. Kawahara Y., et al. Regulation of glutamate receptor RNA editing and ADAR mRNA expression in developing human normal and Down's syndrome brains. Brain Res. Dev. Brain Res. 2004, 148:151-155.
84. Hideyama T., et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J. Neurosci. 2010, 30:11917-11925.
85. Hideyama T., et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol. Dis. 2012, 45:1121-1128.
86. Schneider M.F., et al. Optimal guideRNAs for re-directing deaminase activity of hADAR1 and hADAR2 in trans. Nucleic Acids Res. 2014, 42:e87.
87. Vogel P., et al. Improving site-directed RNA editing in vitro and in cell culture by chemical modification of the guideRNA. Angew. Chem. Int. Ed. Engl. 2014, 53:6267-6271.
88. Stafforst T., Schneider M.F. An RNA-deaminase conjugate selectively repairs point mutations. Angew. Chem. Int. Ed. Engl. 2012, 51:11166-11169.
89. Montiel-Gonzalez M.F., et al. Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18285-18290.
90. Rieder L.E., et al. Tertiary structural elements determine the extent and specificity of messenger RNA editing. Nat. Commun. 2013, 4:2232.
91. Wong S.K., et al. Substrate recognition by ADAR1 and ADAR2. RNA 2001, 7:846-858.
92. Klaue Y., et al. Biochemical analysis and scanning force microscopy reveal productive and nonproductive ADAR2 binding to RNA substrates. RNA 2003, 9:839-846.
93. Enstero M., et al. Recognition and coupling of A-to-I edited sites are determined by the tertiary structure of the RNA. Nucleic Acids Res. 2009, 37:6916-6926.
94. Tian N., et al. A structural determinant required for RNA editing. Nucleic Acids Res. 2011, 39:5669-5681.
95. Rouskin S., et al. Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo. Nature 2014, 505:701-705.
96. Mehta A., et al. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol. Cell. Biol. 2000, 20:1846-1854.
97. Teng B., et al. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993, 260:1816-1819.
98. Chen S.H., et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 1987, 238:363-366.
99. Powell L.M., et al. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 1987, 50:831-840.
100. Rosenberg B.R., et al. Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs. Nat. Struct. Mol. Biol. 2011, 18:230-236.
101. Mukhopadhyay D., et al. C→U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. Am. J. Hum. Genet. 2002, 70:38-50.
102. Yamanaka S., et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:8483-8487.
103. Yamanaka S., et al. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Genes Dev. 1997, 11:321-333.
104. Harris R.S., et al. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 2002, 10:1247-1253.
105. Saraconi G., et al. The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol. 2014, 15:417.